Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield
The crowd is looking at the next couple of years. It should be looking five years into the future.
Overview
Have you ever heard the expression "if it sounds too good to be true, it probably is"? It's an admittedly fair assessment of many offers and prospects, including prospective investments.
It's not always the case, however. Sometimes, things are exactly how they seem on the surface, and the crowd is simply ignoring an opportunity, assuming there's a catch to the apparent upside.
Details
I think that's what's going on with drugmaker Pfizer (NYSE: PFE) of late. Shares of the pharmaceutical outfit have underperformed since late 2021, peaking that year and still down by more than half of that high, pumping up their forward-looking dividend yield to an enticing 6%.
Source
Originally published at www.fool.com.